Hu Liangding
Overview
Explore the profile of Hu Liangding including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
44
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yao S, Na L, Liangding H
Ann Hematol
. 2024 Jun;
103(8):3247-3250.
PMID: 38888615
Here, we present a rare case of myeloproliferative neoplasms (MPN) with eosinophilia harboring both BCR::ABL1 and PDGFRB rearrangements, posing a classification dilemma. The patient exhibited clinical and laboratory features suggestive...
2.
Yao S, Jianlin C, Zhuoqing Q, Yuhang L, Jiangwei H, Guoliang H, et al.
Front Immunol
. 2021 Apr;
12:639217.
PMID: 33868266
Azacitidine is commonly used in the treatment of relapsed acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT), but the effectiveness of this monotherapy...
3.
Zhenyang G, Nainong L, Xiaoxiong W, Maihong W, Xiaorui F, Zhao W, et al.
Cell Transplant
. 2021 Mar;
30:963689721999615.
PMID: 33745341
The number of HLA-haploidentical allogeneic hematopoietic stem-cell transplantation (Haplo-HSCT) is increasing. Comparative studies about Haplo-HSCT versus allo-HSCT with HLA-matched sibling donors (MSD-HSCT) have been tried in leukemias and B-cell lymphomas....
4.
Yao S, Jianlin C, Yarong L, Botao L, Qinghan W, Hongliang F, et al.
Front Oncol
. 2019 Dec;
9:1358.
PMID: 31850234
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) following chemotherapy is part of standard treatment protocol for patients with acute myeloid leukemia (AML). + AML is rare but has an extremely poor...